Bli medlem
Bli medlem

Du är här


Saniona: Saniona approved for listing on Nasdaq First North Premier and publishes company description

Saniona, a leading biotech company in the field of ion channels, today
announces that Saniona has been approved for trading on Nasdaq First
North Premier. Last day of trading on AktieTorget is Wednesday, 18
May 2016, and first day of trading on Nasdaq First North Premier is
Thursday 19 May, 2016.

Saniona will continue to trade under the ticker SANION with the
existing ISIN code SE0005794617. The Company's shareholders do not
need to take any action in connection with the listing.

The Company has compiled a company description that has been approved
by Nasdaq, which from today is available on the Company's website:

Pareto Securities AB will act as Certified Adviser for Saniona on
Nasdaq First North Premier.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail:

About Saniona

Saniona is a research and development company focused on drugs for
diseases of the central nervous system, autoimmune diseases,
metabolic diseases and treatment of pain. The company has a
significant portfolio of potential drug candidates at pre-clinical
and clinical stage. The research is focused on ion channels, which
makes up a unique protein class that enables and controls the passage
of charged ions across cell membranes. Saniona has ongoing
collaboration agreements with Upsher-Smith Laboratories, Inc.,
Productos Medix, S.A de S.V and Saniona's Boston based spinout
Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Inc.
Saniona is based in Copenhagen, Denmark, where it has a research
center of high international standard. Saniona is listed at
AktieTorget since April 2014 and has about 3,700 shareholders. The
company's share is traded under the ticker SANION. Read more at


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.